These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 17409804)
41. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma? Zahid I; Sharif S; Routledge T; Scarci M Interact Cardiovasc Thorac Surg; 2011 May; 12(5):812-7. PubMed ID: 21345818 [TBL] [Abstract][Full Text] [Related]
42. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Fennell DA; C Steele JP; Shamash J; Sheaff MT; Evans MT; Goonewardene TI; Nystrom ML; Gower NH; Rudd RM Lung Cancer; 2005 Feb; 47(2):277-81. PubMed ID: 15639727 [TBL] [Abstract][Full Text] [Related]
43. Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma. Orbaugh KK Clin J Oncol Nurs; 2004 Jun; 8(3):242-7. PubMed ID: 15208818 [TBL] [Abstract][Full Text] [Related]
44. Malignant pleural mesothelioma: a population-based study of survival. Milano MT; Zhang H J Thorac Oncol; 2010 Nov; 5(11):1841-8. PubMed ID: 20975379 [TBL] [Abstract][Full Text] [Related]
45. Pemetrexed in malignant pleural mesothelioma. Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163 [TBL] [Abstract][Full Text] [Related]
47. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898 [TBL] [Abstract][Full Text] [Related]
48. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Steele JP; O'Doherty CA; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM Ann Oncol; 2001 Apr; 12(4):497-9. PubMed ID: 11398882 [TBL] [Abstract][Full Text] [Related]
49. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. O'Connor OA; Horwitz S; Hamlin P; Portlock C; Moskowitz CH; Sarasohn D; Neylon E; Mastrella J; Hamelers R; Macgregor-Cortelli B; Patterson M; Seshan VE; Sirotnak F; Fleisher M; Mould DR; Saunders M; Zelenetz AD J Clin Oncol; 2009 Sep; 27(26):4357-64. PubMed ID: 19652067 [TBL] [Abstract][Full Text] [Related]
50. Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study. Takita H; Mang TS; Loewen GM; Antkowiak JG; Raghavan D; Grajek JR; Dougherty TJ Ann Thorac Surg; 1994 Oct; 58(4):995-8. PubMed ID: 7944821 [TBL] [Abstract][Full Text] [Related]
51. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. Steele JP; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM J Clin Oncol; 2000 Dec; 18(23):3912-7. PubMed ID: 11099320 [TBL] [Abstract][Full Text] [Related]
52. Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. Takeda M; Ohe Y; Horinouchi H; Hida T; Shimizu J; Seto T; Nosaki K; Kishimoto T; Miyashita I; Yamada M; Kaneko Y; Morimoto C; Nakagawa K Lung Cancer; 2019 Nov; 137():64-70. PubMed ID: 31557561 [TBL] [Abstract][Full Text] [Related]
53. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. Garland LL; Chansky K; Wozniak AJ; Tsao AS; Gadgeel SM; Verschraegen CF; Dasilva MA; Redman M; Gandara DR J Thorac Oncol; 2011 Nov; 6(11):1938-45. PubMed ID: 21964533 [TBL] [Abstract][Full Text] [Related]
54. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. Duvic M; Kim YH; Zinzani PL; Horwitz SM Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509 [No Abstract] [Full Text] [Related]
55. A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer. Ho AL; Lipson BL; Sherman EJ; Xiao H; Fury MG; Apollo A; Seetharamu N; Sima CS; Haque S; Lyo JK; Sales R; Cox L; Pfister DG Invest New Drugs; 2014 Jun; 32(3):549-54. PubMed ID: 24566705 [TBL] [Abstract][Full Text] [Related]
56. Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts. Tedeschi PM; Kathari YK; Farooqi IN; Bertino JR Cancer Chemother Pharmacol; 2014 Nov; 74(5):1029-32. PubMed ID: 25205429 [TBL] [Abstract][Full Text] [Related]
57. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Sahmoud T; Postmus PE; van Pottelsberghe C; Mattson K; Tammilehto L; Splinter TA; Planting AS; Sutedja T; van Pawel J; van Zandwijk N; Baas P; Roozendaal KJ; Schrijver M; Kirkpatrick A; Van Glabbeke M; Ardizzoni A; Giaccone G Eur J Cancer; 1997 Nov; 33(13):2211-5. PubMed ID: 9470808 [TBL] [Abstract][Full Text] [Related]
59. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. Curran D; Sahmoud T; Therasse P; van Meerbeeck J; Postmus PE; Giaccone G J Clin Oncol; 1998 Jan; 16(1):145-52. PubMed ID: 9440736 [TBL] [Abstract][Full Text] [Related]
60. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. Fennell DA; McDowell C; Busacca S; Webb G; Moulton B; Cakana A; O'Byrne KJ; Meerbeeck JV; Donnellan P; McCaffrey J; Baas P J Thorac Oncol; 2012 Sep; 7(9):1466-70. PubMed ID: 22895144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]